Liraglutide Resulted in 36% Loss in Excess Body Weight - Medscape News

May 22, 2012 (Lyon, France) — Obese individuals taking 3 mg of liraglutide daily who completed a 1-year study lost a mean 35.6% of excess body weight. The number needed to treat (NNT) to achieve a loss of 10% of total body weight was only 3, Nick Finer ...

The Human GLP-1 Analog Liraglutide and the Pancreas - Medscape News

Glucagon-like peptide (GLP)-1 analogs have been implicated as a risk factor for pancreatitis in humans. We investigated whether liraglutide, the once-daily human GLP-1 analog, induces pancreatitis in rats, mice, and monkeys. Pancreata from mice ...

Obese patients might benefit from liraglutide treatment - SmartBrief

A study presented at the European Congress on Obesity revealed obese patients treated with liraglutide lost more weight than those who took a placebo or orlistat. Researchers also found that daily intake of 3 mg of liraglutide for one year resulted in a ...

Novo obesity drug seen with 43 percent chance of approval - Chicago Tribune

Liraglutide, an active ingredient in Victoza, has shown it can be effective in helping obese people losing weight. A survey of 10 analysts found an average forecast of a 43 percent chance of Victoza being approved by the U.S. Food and Drug ...

Bydureon FDA Approval: Physician Opinion - new market research report - Transworld News

This survey shows broad enthusiasm for the drug among endocrinologists and PCPs, but initial excitement may wane as physicians fully weigh such factors as comparative efficacy with Novo Nordisk's Victoza (liraglutide), injection device size and convenience ...

Type 2 Diabetes - Global Drug Forecasts and Treatment Analysis to 2020 - new market research report - Transworld News

such as Levemir (insulin detemir), Byetta (exenatide), Januvia (sitagliptin), and Victoza (liraglutide). The annual cost of therapy was also driven by the increased use of multiple drugs per patient and the adoption of combination therapies, such as ...